<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10</volume><submitter>Amado CA</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>MOTS-c and Romo1 are mitochondrial peptides that are modulated by oxidative stress. No previous studies have explored circulating levels of MOTS-c in patients with chronic obstructive pulmonary disease (COPD).&lt;h4>Methods&lt;/h4>We enrolled 142 patients with stable COPD and 47 smokers with normal lung function in an observational cross-sectional study. We assessed serum levels of both MOTS-c and Romo1 and associated these findings with clinical characteristics of COPD.&lt;h4>Results&lt;/h4>Compared with smokers with normal lung function, patients with COPD had lower levels of MOTS-c (&lt;i>p&lt;/i> = 0.02) and higher levels of Romo1 (&lt;i>p&lt;/i> = 0.01). A multivariate logistic regression analysis revealed that above-median MOTS-c levels were positively associated with Romo1 levels (OR 1.0</pubmed_abstract><journal>Frontiers in medicine</journal><pagination>1100211</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9944395</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Circulating levels of mitochondrial oxidative stress-related peptides MOTS-c and Romo1 in stable COPD: A cross-sectional study.</pubmed_title><pmcid>PMC9944395</pmcid><pubmed_authors>Ferrer-Pargada D</pubmed_authors><pubmed_authors>Lavin BA</pubmed_authors><pubmed_authors>Guerra AR</pubmed_authors><pubmed_authors>Martin F</pubmed_authors><pubmed_authors>Garcia-Unzueta M</pubmed_authors><pubmed_authors>Amado CA</pubmed_authors><pubmed_authors>Martin-Audera P</pubmed_authors><pubmed_authors>Aguero J</pubmed_authors><pubmed_authors>Boucle D</pubmed_authors><pubmed_authors>Casanova C</pubmed_authors><pubmed_authors>Berja A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Circulating levels of mitochondrial oxidative stress-related peptides MOTS-c and Romo1 in stable COPD: A cross-sectional study.</name><description>&lt;h4>Background&lt;/h4>MOTS-c and Romo1 are mitochondrial peptides that are modulated by oxidative stress. No previous studies have explored circulating levels of MOTS-c in patients with chronic obstructive pulmonary disease (COPD).&lt;h4>Methods&lt;/h4>We enrolled 142 patients with stable COPD and 47 smokers with normal lung function in an observational cross-sectional study. We assessed serum levels of both MOTS-c and Romo1 and associated these findings with clinical characteristics of COPD.&lt;h4>Results&lt;/h4>Compared with smokers with normal lung function, patients with COPD had lower levels of MOTS-c (&lt;i>p&lt;/i> = 0.02) and higher levels of Romo1 (&lt;i>p&lt;/i> = 0.01). A multivariate logistic regression analysis revealed that above-median MOTS-c levels were positively associated with Romo1 levels (OR 1.0</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2025-04-04T14:17:45.964Z</modification><creation>2025-02-19T02:24:00.205Z</creation></dates><accession>S-EPMC9944395</accession><cross_references><pubmed>36844198</pubmed><doi>10.3389/fmed.2023.1100211</doi></cross_references></HashMap>